Skip to main content
SpringerLink
Log in

Implications of Hyperthermic Intraperitoneal Chemotherapy Perfusion-Related Hyperglycemia

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Hyperthermic intraperitoneal chemotherapy (HIPEC) administration can be associated with hyperglycemia during perfusion. Little is known about this effect, and no previous studies have examined patient characteristics associated with perfusion-related hyperglycemia.

Methods

We retrospectively identified consecutive patients at a single institution treated with HIPEC from 8/2003 to 10/2016 who had intraoperative blood glucose measured. Hypertonic 1.5% dextrose-containing peritoneal dialysate was used as carrier solution in all patients. Comparisons were made using parametric [Student’s t test, analysis of variance (ANOVA)], and nonparametric tests (χ 2, Kruskal–Wallis) where appropriate.

Results

There were 85 patients identified, with average age of 53 ± 12 years, 69 (81%) with appendiceal or colorectal peritoneal cancer. Most patients were perfused with mitomycin C (69%) or oxaliplatin (24%). Intraoperative hyperglycemia (> 180 mg/dL) affected the majority of patients (86%), with values up to 651 mg/dL. Insulin was required for treatment in 66% of patients. Peak hyperglycemia occurred within an hour of perfusion in 91%, and resolved by postoperative day one in 91% of patients. Glucose > 309 mg/dL (highest quartile) was associated with longer operating time (p = 0.03) and with use of oxaliplatin compared with mitomycin C (p = 0.01). No association was found with other comorbidities, peritoneal carcinomatosis index score, or postoperative outcomes.

Conclusions

Most patients experience hyperglycemia during HIPEC. This is not clearly associated with patient factors, and may be due to use of dextrose-containing carrier solution. Since perioperative hyperglycemia has potential negative impact, use of dextrose-containing carrier solution should be questioned and is worth investigating further.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005; 130:1144.e1–1144.e8.

    Article  Google Scholar 

  2. Gandhi GY, Nuttall GA, Abel MD, et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc. 2005; 80:862–866.

    Article  PubMed  Google Scholar 

  3. Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg. 2013; 257:8–14.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Park C, Hsu C, Neelakanta G, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009; 87:1031–1036.

    Article  PubMed  Google Scholar 

  5. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21:3737–3743.

    Article  PubMed  Google Scholar 

  6. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008; 15:2426–2432.

    Article  PubMed  Google Scholar 

  7. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28:63–68.

    Article  PubMed  Google Scholar 

  8. Elias D, Honoré C, Ciuchendéa R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008; 95:1164–1171.

    Article  CAS  PubMed  Google Scholar 

  9. Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev. 2016; 48:42–49.

    Article  PubMed  Google Scholar 

  10. Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014; 21:1501–1505.

    Article  CAS  PubMed  Google Scholar 

  11. González-Moreno S1, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010; 2:68–75

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008; 98:247–252.

    Article  PubMed  Google Scholar 

  13. Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006; 57:703–708.

    Article  CAS  PubMed  Google Scholar 

  14. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of surgical oncology. Ann Surg Oncol. 2007; 14:128–133.

    Article  CAS  PubMed  Google Scholar 

  15. De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, Mortier E. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008; 28:61–66.

    PubMed  Google Scholar 

  16. Rueth NM, Murray SE, Huddleston SJ, Abbott AM, Greeno EW, Kirstein MN, Tuttle TM. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011; 18:174–180.

    Article  PubMed  Google Scholar 

  17. Mehta AM, Van den Hoven JM, Rosing H, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015; 479:23–27.

    Article  CAS  PubMed  Google Scholar 

  18. Twardowski ZJ, Nolph KD, Rhanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP. Peritoneal equilibrium test. Perit Dial Bull. 1987; 7:138–147.

    Google Scholar 

  19. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345:1359–1367.

    Article  PubMed  Google Scholar 

  20. Russo N. Perioperative glycemic control. Anesthesiol Clin. 2012; 30:445–466.

    Article  PubMed  Google Scholar 

  21. Kwon S, Thompson R, Dellinger P, Yanez D. Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg. 2013; 257:8–14.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001; 24:371–381.

    Article  CAS  PubMed  Google Scholar 

  23. Lazar HL, McDonnell M, Chipkin SR, et al. The society of thoracic surgeons practice guideline series: blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009; 87:663–669.

    Article  PubMed  Google Scholar 

  24. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin North Am. 2003; 12:813–824.

    Article  Google Scholar 

  25. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001; 47:269–276.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

None

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Colorado School of Medicine, Aurora, CO, USA

    Camille L. Stewart MD, Ana Gleisner MD, Alison Halpern MD, Irada Ibrahim-Zada MD, Rodrigo Asturias Luna MD, Nathan Pearlman MD, Csaba Gajdos MD, Barish Edil MD & Martin McCarter MD

Authors
  1. Camille L. Stewart MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Gleisner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alison Halpern MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irada Ibrahim-Zada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rodrigo Asturias Luna MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nathan Pearlman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Csaba Gajdos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Barish Edil MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martin McCarter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Camille L. Stewart MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stewart, C.L., Gleisner, A., Halpern, A. et al. Implications of Hyperthermic Intraperitoneal Chemotherapy Perfusion-Related Hyperglycemia. Ann Surg Oncol 25, 655–659 (2018). https://doi.org/10.1245/s10434-017-6284-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-6284-6

Keywords

Search

Navigation